Compare BVS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | ADCT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.9M | 484.4M |
| IPO Year | 2016 | 2019 |
| Metric | BVS | ADCT |
|---|---|---|
| Price | $8.80 | $4.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $14.25 | $7.50 |
| AVG Volume (30 Days) | 293.3K | ★ 801.2K |
| Earning Date | 01-01-0001 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | 44.90 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $568,087,000.00 | $70,837,000.00 |
| Revenue This Year | $7.42 | $14.96 |
| Revenue Next Year | $6.46 | $1.06 |
| P/E Ratio | $25.41 | ★ N/A |
| Revenue Growth | N/A | ★ 1.84 |
| 52 Week Low | $5.81 | $1.05 |
| 52 Week High | $11.25 | $4.80 |
| Indicator | BVS | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 68.24 |
| Support Level | $6.42 | $3.79 |
| Resistance Level | $9.01 | N/A |
| Average True Range (ATR) | 0.39 | 0.27 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 46.67 | 83.66 |
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).